Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Approves Gilead’s Remdesivir For COVID-19 In Record Time

Despite The Controversy, Blockbuster Status Is Predicted

Executive Summary

The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about 2,000 per treatment.

You may also be interested in...



EU Accelerated Assessment Tracker

Sanofi failed in its attempt to have its EU marketing authorization application for avalglucosidase alfa fast-tracked through the centralized review process at the European Medicines Agency. This and other developments relating to the agency's accelerated assessment mechanism are logged in this latest update to the Pink Sheet's EU accelerated assessment tracker.

Second COVID-19 Vaccine Undergoes ‘Rolling Review’ By EMA

The European Medicines Agency is fast-tracking its review of the vaccine that BioNTech and Pfizer are developing and testing in Phase III trials.

Rasi To Ombudsman: No Risk Of Bias In EMA’s COVID-19 Drug Evaluations

European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel